DexCom (DXCM) exemplifies the GARP strategy, offering strong revenue & earnings growth, high profitability, and a reasonable valuation within its high-growth industry.
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals.
This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses will continue prospering by anchoring themselves in unique market segments.
A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies.
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many shareholders. This may have investors wondering how to approach the situation.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers.
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
U.S. equities took a breather on Tuesday, stabilizing after Monday's sharp rally as investors awaited a House vote on the temporary spending bill expected to end the record-long government shutdown later this week.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions.
While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session.
DexCom's third quarter was met with a negative market reaction despite outpacing Wall Street’s revenue and adjusted EPS expectations. Management attributed quarterly growth to increased continuous glucose monitoring (CGM) adoption among people with type 2 diabetes, particularly following expanded insurance coverage and deeper reach into primary care. Interim CEO Jacob Leach emphasized the impact of new product features and improved access, but also acknowledged lingering manufacturing and sensor deployment issues that affected sensor supply and user experience. As Leach stated, "We have addressed deployment challenges and continue to improve sensor quality, but will not be satisfied until every customer expectation is met."
The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future.
A select few continue to execute at a high level, growing their market dominance and delivering strong returns.
